Comment from Boehringer Ingelheim

Summary: Boehringer Ingelheim Pharmaceuticals, Inc. provides specific technical comments and proposed revisions to the draft guidance on protocol deviations for clinical investigations. The company seeks to clarify reporting timeframes, the distinction between safety and data integrity issues, and the classification of deviations at the site versus participant level.